BDBM179873 US10231963, Table B.17::US10287250, Compound B.1::US10736890, Compound TABLE B.17::US10752592, Compound TABLE B.1::US11534436, Compound Table B.17::US9133125, Table B, Compound 1::US9656961, Example 00134

SMILES NC(=O)c1ccc2C[C@H]3N(CC4CCC4)CC[C@@]4(CCCC[C@@]34O)c2c1O

InChI Key InChIKey=SIJATVAZXUYZQN-VOQZNFBZSA-N

Data  7 KI  7 IC50  5 EC50

  Tab Delimited (TSV)   2D SDfile   Computed 3D by Vconf -m prep SDfile
Find this compound or compounds like it in BindingDB:
   Substructure
Similarity at least:  must be >=0.5
Exact match

Activity Spreadsheet -- Enzyme Inhibition Constant Data from BindingDB

Found 18 hits for monomerid = 179873   

TargetMu-type opioid receptor(Homo sapiens (Human))
Alkermes Pharma Ireland

US Patent
LigandPNGBDBM179873(US10231963, Table B.17 | US10287250, Compound B.1 ...)
Affinity DataKi:  0.280nM ΔG°:  -13.0kcal/mole IC50:  4.20nMpH: 7.5 T: 2°CAssay Description:The Ki (binding affinity) for u opioid receptors was determined using a competitive displacement assay as previously described in Neumeyer (Journal o...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetMu-type opioid receptor(Homo sapiens (Human))
Alkermes Pharma Ireland

US Patent
LigandPNGBDBM179873(US10231963, Table B.17 | US10287250, Compound B.1 ...)
Affinity DataKi:  0.280nMAssay Description:The Ki (binding affinity) for opioid receptors was determined using a competitive displacement assay as previously described in Neumeyer (Journal of ...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetMu-type opioid receptor(Homo sapiens (Human))
Alkermes Pharma Ireland

US Patent
LigandPNGBDBM179873(US10231963, Table B.17 | US10287250, Compound B.1 ...)
Affinity DataKi:  0.280nMAssay Description:The Ki (binding affinity) for μ opioid receptors was determined using a competitive displacement assay as previously described in Neumeyer (Jour...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetMu-type opioid receptor(Homo sapiens (Human))
Alkermes Pharma Ireland

US Patent
LigandPNGBDBM179873(US10231963, Table B.17 | US10287250, Compound B.1 ...)
Affinity DataKi:  0.280nMAssay Description:The Ki (binding affinity) for μ opioid receptors was determined using a competitive displacement assay as previously described in Neumeyer (Jour...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetMu-type opioid receptor(Homo sapiens (Human))
Alkermes Pharma Ireland

US Patent
LigandPNGBDBM179873(US10231963, Table B.17 | US10287250, Compound B.1 ...)
Affinity DataKi:  0.280nMAssay Description:The Ki (binding affinity) for μ opioid receptors was determined using a competitive displacement assay as previously described in Neumeyer (Jour...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetMu-type opioid receptor(Homo sapiens (Human))
Alkermes Pharma Ireland

US Patent
LigandPNGBDBM179873(US10231963, Table B.17 | US10287250, Compound B.1 ...)
Affinity DataKi:  0.280nMAssay Description:The Ki (binding affinity) for μ opioid receptors was determined using a competitive displacement assay as previously described in Neumeyer (Jour...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetMu-type opioid receptor(Homo sapiens (Human))
Alkermes Pharma Ireland

US Patent
LigandPNGBDBM179873(US10231963, Table B.17 | US10287250, Compound B.1 ...)
Affinity DataKi:  0.280nMAssay Description:The Ki (binding affinity) for opioid receptors was determined using a competitive displacement assay as previously described in Neumeyer (Journal of ...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetMu-type opioid receptor(Homo sapiens (Human))
Alkermes Pharma Ireland

US Patent
LigandPNGBDBM179873(US10231963, Table B.17 | US10287250, Compound B.1 ...)
Affinity DataIC50:  4.20nMAssay Description:The Ki (binding affinity) for μ opioid receptors was determined using a competitive displacement assay as previously described in Neumeyer (Jour...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetMu-type opioid receptor(Homo sapiens (Human))
Alkermes Pharma Ireland

US Patent
LigandPNGBDBM179873(US10231963, Table B.17 | US10287250, Compound B.1 ...)
Affinity DataIC50:  4.20nMAssay Description:The Ki (binding affinity) for μ opioid receptors was determined using a competitive displacement assay as previously described in Neumeyer (Jour...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetMu-type opioid receptor(Homo sapiens (Human))
Alkermes Pharma Ireland

US Patent
LigandPNGBDBM179873(US10231963, Table B.17 | US10287250, Compound B.1 ...)
Affinity DataEC50:  1.40nMAssay Description:The Ki (binding affinity) for opioid receptors was determined using a competitive displacement assay as previously described in Neumeyer (Journal of ...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetMu-type opioid receptor(Homo sapiens (Human))
Alkermes Pharma Ireland

US Patent
LigandPNGBDBM179873(US10231963, Table B.17 | US10287250, Compound B.1 ...)
Affinity DataIC50:  4.20nMAssay Description:The Ki (binding affinity) for opioid receptors was determined using a competitive displacement assay as previously described in Neumeyer (Journal of ...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetMu-type opioid receptor(Homo sapiens (Human))
Alkermes Pharma Ireland

US Patent
LigandPNGBDBM179873(US10231963, Table B.17 | US10287250, Compound B.1 ...)
Affinity DataIC50:  4.20nMAssay Description:The Ki (binding affinity) for μ opioid receptors was determined using a competitive displacement assay as previously described in Neumeyer (Jour...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetMu-type opioid receptor(Homo sapiens (Human))
Alkermes Pharma Ireland

US Patent
LigandPNGBDBM179873(US10231963, Table B.17 | US10287250, Compound B.1 ...)
Affinity DataEC50:  1.40nMpH: 7.4Assay Description:The EC50 and Imax for μ opioid receptors was determined using a [I35S]GTPγS binding assay. This assay measures the functional properties of a compo...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetMu-type opioid receptor(Homo sapiens (Human))
Alkermes Pharma Ireland

US Patent
LigandPNGBDBM179873(US10231963, Table B.17 | US10287250, Compound B.1 ...)
Affinity DataIC50:  4.20nMAssay Description:The Ki (binding affinity) for μ opioid receptors was determined using a competitive displacement assay as previously described in Neumeyer (Jour...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetMu-type opioid receptor(Homo sapiens (Human))
Alkermes Pharma Ireland

US Patent
LigandPNGBDBM179873(US10231963, Table B.17 | US10287250, Compound B.1 ...)
Affinity DataIC50:  4.20nMAssay Description:The Ki (binding affinity) for opioid receptors was determined using a competitive displacement assay as previously described in Neumeyer (Journal of ...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetMu-type opioid receptor(Homo sapiens (Human))
Alkermes Pharma Ireland

US Patent
LigandPNGBDBM179873(US10231963, Table B.17 | US10287250, Compound B.1 ...)
Affinity DataEC50:  1.40nMAssay Description:The Ki (binding affinity) for opioid receptors was determined using a competitive displacement assay as previously described in Neumeyer (Journal of ...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetMu-type opioid receptor(Homo sapiens (Human))
Alkermes Pharma Ireland

US Patent
LigandPNGBDBM179873(US10231963, Table B.17 | US10287250, Compound B.1 ...)
Affinity DataEC50:  1.40nMAssay Description:The Ki (binding affinity) for μ opioid receptors was determined using a competitive displacement assay as previously described in Neumeyer (Jour...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetMu-type opioid receptor(Homo sapiens (Human))
Alkermes Pharma Ireland

US Patent
LigandPNGBDBM179873(US10231963, Table B.17 | US10287250, Compound B.1 ...)
Affinity DataEC50:  1.40nMAssay Description:The EC50 and Imax for μ opioid receptors was determined using a [35S]GTPγS binding assay. This assay measures the functional properties of ...More data for this Ligand-Target Pair
In DepthDetails US Patent